.Nature Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a typical follow-up of 11 months, clients with metastatic intestinal tumors that got biomarker-matched treatments based on flowing cyst DNA profiling showed a higher professional advantage than those acquiring unrivaled therapy.